首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學分子標靶治療學細胞療法基因療法

市場調查報告書

商品編碼

1624394

全球分子細胞遺傳學市場規模（按產品、技術、應用、地區、範圍和預測）

Global Molecular Cytogenetics Market Size By Product, By Technique (Fluorescence In Situ Hybridization, Comparative Genomic Hybridization ), By Application, By Geographic Scope And Forecast

出版日期: 2024年07月13日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

分子細胞遺傳學的市場規模與預測

預計 2024 年分子細胞遺傳學市場規模將達到 25.7 億美元，到 2031 年將達到 51.5 億美元，2024 年至 2031 年的複合年增長率為 10%。分子細胞遺傳學涉及使用分子技術（例如螢光原位雜交 (FISH)、比較基因組雜交 (CGH) 和分子克隆）來研究染色體。這使得研究人員能夠分析染色體異常、基因圖譜，並瞭解染色體內遺傳物質的組織。分子細胞遺傳學技術在臨床上廣泛應用於診斷由染色體異常引起的遺傳疾病。例如，FISH 可以檢測與唐氏症和各種癌症等疾病相關的特定基因序列。瞭解癌細胞的染色體異常對於癌症的診斷、預後和治療至關重要。 CGH 和 FISH 用於檢測導致癌症進展和抗藥性的基因變化。

產前診斷透過使用 FISH 和陣列 CGH 等技術檢測胎兒的染色體異常發揮重要作用。

它對於基因組繪圖和瞭解基因組結構變異也很有用。這對於研究演化生物學、群體遺傳學以及性狀和疾病的遺傳基礎具有重要意義。

分子和影像技術的不斷進步將提高分子細胞遺傳學的分辨率、準確性和效率。這將允許對染色體結構和功能進行更詳細的分析。

分子細胞遺傳學的全球市場動態

主要市場驅動因子

技術進步：

FISH、CGH等基因組技術的持續創新，提高了染色體分析的準確性、靈敏度和效率，擴大了其在臨床診斷和研究中的應用範圍，從而推動市場成長。

遺傳疾病和癌症發生率不斷上升：

全球遺傳疾病和癌症的發生率不斷上升，推動了對能夠檢測染色體異常並指導個人化治療策略的精準診斷工具的需求。

轉變為個人化醫療的：

分子細胞遺傳學能夠識別影響疾病易感性和治療結果的遺傳標記和異常，在個人化醫療中發揮關鍵作用。

增加醫療支出：

全球醫療保健支出的增加將支持對包括分子細胞遺傳學在內的先進診斷技術的投資，從而推動市場成長。

策略合作與夥伴關係：

學術界、研究機構和產業參與者之間的合作加速了創新分子細胞遺傳學解決方案的開發和市場發展。

支持性監理環境：

良好的監管政策和指導方針簡化了分子細胞遺傳學產品的批准流程，促進了投資和市場成長。

注重早期診斷與積極醫療保健：

分子細胞遺傳學檢測能夠早期發現遺傳疾病和癌症，使臨床醫生能夠及時採取乾預措施並改善患者的治療效果。

主要問題

技術複雜性與成本：

FISH 和 CGH 等先進的分子細胞遺傳學技術需要精密的設備、專門的試劑和熟練的人力，這增加了總體成本，從而阻礙了市場的成長。

解釋與標準化：

由於協議、數據解釋和實驗室間標準化的多變性，對分子細胞遺傳學產生的複雜染色體數據的分析和解釋具有課題性。

監理障礙：

新的分子細胞遺傳學測試的嚴格監管要求和冗長的審批流程可能會減緩市場進入和創新。

兌換問題：

限制性報銷政策和不同的分子細胞遺傳學測試報銷率可能會阻礙醫療保健提供者採用該技術，從而阻礙市場成長。

融入臨床實務：

將分子細胞遺傳學檢測整合到現有的臨床工作流程和醫療保健系統中可能具有課題性，需要基礎設施投資和工作流程調整。

教育與意識障礙：

醫療保健提供者和患者對分子細胞遺傳技術的認識和理解有限，可能會阻礙其採用和使用。

競爭格局：

市場參與者之間的激烈競爭和技術的快速進步需要不斷創新和差異化，以保持市場佔有率和盈利能力。

主要趨勢

技術進步：

基因組技術的持續創新，包括次世代定序 (NGS)、單細胞定序和數位 PCR，正在提高分子細胞遺傳學檢測的靈敏度、解析度和通量。

整合多組學方法：

將細胞遺傳學數據與基因組、轉錄組和表觀基因組數據（多組學）結合，可以全面瞭解遺傳疾病和癌症，並促進個人化醫療。

液體切片的興起：

液體活檢技術，包括循環腫瘤 DNA (ctDNA) 分析和無細胞 DNA (cfDNA) 定序，越來越多地用於非侵入性檢測和監測癌症中的染色體異常。

自動化與機器人技術：

分子細胞遺傳學實驗室中自動化和機器人技術的實施簡化了工作流程，減少了實際操作時間，並提高了檢測的可重複性和可擴展性。

精準醫療計畫：

對精準醫療的日益重視促使了對分子細胞遺傳學測試的需求增加，這種測試可以識別特定的遺傳標記來指導標靶治療。

Molecular Cytogenetics Market size was valued at USD 2.57 Billion in 2024 and is projected to reach USD 5.15 Billion by 2031, growing at a CAGR of 10% from 2024 to 2031. Molecular cytogenetics involves the use of molecular techniques such as fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and molecular cloning to study chromosomes. It allows researchers to analyze chromosomal abnormalities, gene mapping, and understand the organization of genetic material within chromosomes. Molecular cytogenetic techniques are extensively used in clinical settings to diagnose genetic disorders caused by chromosomal abnormalities. FISH, for example, can detect specific genetic sequences associated with diseases like Down syndrome or various cancers. Understanding chromosomal abnormalities in cancer cells is crucial for cancer diagnosis, prognosis, and treatment. CGH and FISH are used to detect genetic changes that drive cancer progression and drug resistance.

It plays a vital role in prenatal diagnosis, detecting chromosomal abnormalities in fetuses using techniques like FISH or array CGH.

It helps in genome mapping and understanding the structural variations in genomes. This is important for studying evolutionary biology, population genetics, and the genetic basis of traits and diseases.

Continued advancements in molecular techniques and imaging technologies will enhance the resolution, accuracy, and efficiency of molecular cytogenetics. This will allow for more detailed analysis of chromosomal structures and functions.

Global Molecular Cytogenetics Market Dynamics

The key market dynamics that are shaping the global molecular cytogenetics market include:

Key Market Drivers

Technological Advancements:

Continuous innovation in genomic technologies, such as FISH and CGH, enhances the accuracy, sensitivity, and efficiency of chromosomal analysis, thereby expanding the application areas in clinical diagnostics and research, this enables growth of the market.

Increasing Prevalence of Genetic Disorders and Cancer:

The rising incidence of genetic diseases and cancers worldwide fuels the demand for precise diagnostic tools that can detect chromosomal abnormalities and guide personalized treatment strategies.

Shift towards Personalized Medicine:

Molecular cytogenetics plays a pivotal role in personalized medicine by enabling the identification of genetic markers and abnormalities that influence disease susceptibility and treatment response.

Growing Healthcare Expenditure:

Rising healthcare spending globally supports investments in advanced diagnostic technologies, including molecular cytogenetics, driving market growth.

Strategic Collaborations and Partnerships:

Collaborative efforts between academia, research institutions, and industry players facilitate the development of innovative molecular cytogenetic solutions and expand market reach.

Supportive Regulatory Environment:

Favorable regulatory policies and guidelines streamline the approval process for molecular cytogenetic products, encouraging investment and market growth.

Focus on Early Diagnosis and Proactive Healthcare:

Molecular cytogenetic tests enable early detection of genetic disorders and cancers, empowering clinicians to initiate timely interventions and improve patient outcomes.

Key Challenges:

Complexity and Cost of Technology:

Advanced molecular cytogenetic techniques such as FISH and CGH require sophisticated equipment, specialized reagents, and skilled personnel, increasing overall costs which is hindering the growth of the market.

Interpretation and Standardization:

Analyzing and interpreting complex chromosomal data generated by molecular cytogenetics poses challenges due to variability in protocols, data interpretation, and standardization across laboratories.

Regulatory Hurdles:

Stringent regulatory requirements and lengthy approval processes for new molecular cytogenetic assays can delay market entry and innovation.

Reimbursement Issues:

Limited reimbursement policies and variability in reimbursement rates for molecular cytogenetic tests may hinder adoption among healthcare providers and hamper market growth.

Integration with Clinical Practice:

Integrating molecular cytogenetic tests into existing clinical workflows and healthcare systems can be challenging, requiring infrastructure investments and workflow adjustments.

Educational and Awareness Barriers:

Limited awareness and understanding of molecular cytogenetic technologies among healthcare providers and patients may hinder adoption and utilization.

Competitive Landscape:

Intense competition among market players and rapid technological advancements necessitate continuous innovation and differentiation to maintain market share and profitability.

Key Trends

Advancements in Technology:

Continuous innovation in genomic technologies, such as next-generation sequencing (NGS), single-cell sequencing, and digital PCR, is enhancing the sensitivity, resolution, and throughput of molecular cytogenetic assays.

Integration of Multi-Omics Approaches:

Combining cytogenetic data with genomic, transcriptomic, and epigenomic data (multi-omics) provides a comprehensive understanding of genetic disorders and cancers, facilitating personalized medicine.

Rise of Liquid Biopsies:

Liquid biopsy techniques, including circulating tumor DNA (ctDNA) analysis and cell-free DNA (cfDNA) sequencing, are increasingly used for non-invasive detection and monitoring of chromosomal abnormalities in cancers.

Automation and Robotics:

Adoption of automation and robotics in molecular cytogenetics laboratories streamlines workflows, reduces hands-on time, and improves assay reproducibility and scalability.

Precision Medicine Initiatives:

Growing emphasis on precision medicine initiatives is driving demand for molecular cytogenetic tests that can identify specific genetic markers and guide targeted therapies.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Molecular Cytogenetics Market Regional Analysis

Here is a more detailed regional analysis of the global molecular cytogenetics market:

North America

North America is expected to dominate the molecular cytogenetics market. The region boasts well-established healthcare facilities equipped with state-of-the-art diagnostic technologies. This infrastructure supports the widespread adoption of molecular cytogenetic tests across various clinical settings, from hospitals to research laboratories.

The United States and Canada have robust regulatory agencies like the FDA (Food and Drug Administration) and Health Canada, respectively. These agencies enforce clear guidelines and stringent regulatory standards for the approval and commercialization of molecular cytogenetic products. This regulatory clarity accelerates the market entry of new technologies, ensuring timely availability to healthcare providers and patients.

There is a notable increase in the incidence of cancers and genetic disorders in North America. This demographic trend drives the demand for molecular cytogenetic tests that can precisely diagnose chromosomal abnormalities associated with these diseases. Moreover, the emphasis on personalized medicine encourages the use of molecular cytogenetics to tailor treatment strategies based on individual genetic profiles.

North America is a hub for technological innovation in healthcare. The presence of leading market players, research institutions, and universities fosters continuous R&D in molecular cytogenetics. This results in the development of cutting-edge technologies and diagnostic assays that enhance accuracy, sensitivity, and efficiency in chromosomal analysis.

Asia Pacific

Asia Pacific is indeed experiencing rapid growth in the molecular cytogenetics market. Countries in Asia Pacific such as China, India, and Southeast Asian nations are witnessing significant increases in healthcare expenditure and improvements in healthcare infrastructure. This expansion supports greater accessibility to advanced diagnostic technologies, including molecular cytogenetics, across both urban and rural areas.

There is a notable rise in the prevalence of chronic diseases like cancer and genetic disorders in Asia Pacific. This demographic shift is fueling the demand for accurate and early diagnostic solutions provided by molecular cytogenetics. The ability to detect chromosomal abnormalities plays a crucial role in early intervention and personalized treatment planning.

The region is seeing rapid adoption of new technologies in healthcare, driven by increasing investments in research and development. This includes advancements in genomic technologies, automation in laboratory processes, and the integration of AI and machine learning in data analysis. These advancements enhance the capabilities and efficiency of molecular cytogenetic assays, making them more accessible and cost-effective.

Asia Pacific offers vast untapped market potential for molecular cytogenetics due to rising awareness about personalized medicine and genetic testing. As healthcare providers and patients become more informed about the benefits of genetic diagnostics, there is a growing willingness to invest in these technologies to improve healthcare outcomes.

Global Molecular Cytogenetics Market: Segmentation Analysis

The Global Molecular Cytogenetics Market is Segmented on the basis of Product, Technique, Application, And Geography.

Molecular Cytogenetics Market, By Product

Kits & Reagent
Instruments
Consumables
Software & Services

Based on Product, the Global Molecular Cytogenetics Market is bifurcated into Kits & Reagent, Instruments, Consumables, and Software & Services. In the molecular cytogenetics market, instruments emerge as the dominating product segment. These instruments include advanced equipment and platforms essential for performing molecular cytogenetic techniques such as Fluorescence In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), and array CGH. Instruments are crucial for automating and streamlining the process of chromosomal analysis, enhancing laboratory efficiency and accuracy. The continuous innovation in instrument technology, including improvements in resolution, sensitivity, and throughput, further solidifies their dominance in the market. As laboratories and research facilities worldwide upgrade their capabilities to meet the growing demand for molecular cytogenetic testing, instruments play a pivotal role in supporting these diagnostic and research applications. Software and services represent the rapidly growing segment within the molecular cytogenetics market.

Molecular Cytogenetics Market, By Technique

Fluorescence In Situ Hybridization (FISH)
Comparative Genomic Hybridization (CGH)
Genomic In Situ Hybridization (GISH)
Array Comparative Genomic Hybridization (ACGH)

Based on Technique, the Global Molecular Cytogenetics Market is bifurcated into Fluorescence In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Genomic In Situ Hybridization (GISH), Array Comparative Genomic Hybridization (ACGH). In the molecular cytogenetics market, Fluorescence In Situ Hybridization (FISH) stands out as the dominating technique due to its widespread adoption in both clinical diagnostics and research applications. FISH offers high specificity and sensitivity in detecting chromosomal abnormalities and genetic rearrangements, making it indispensable in identifying cancer biomarkers, diagnosing genetic disorders like Down syndrome, and monitoring disease progression. Its versatility across various clinical specialties, including oncology, prenatal diagnostics, and infectious diseases, contributes significantly to its dominance in the market. Comparative Genomic Hybridization (CGH) emerges as the rapidly growing segment within molecular cytogenetics.

Molecular Cytogenetics Market, By Application

Genetic Disorders
Oncology
Personalized Medicine

Based on Application, the Global Molecular Cytogenetics Market is bifurcated into Genetic Disorders, Oncology, and Personalized Medicine. In the molecular cytogenetics market, oncology emerges as the dominating application segment due to its critical role in cancer diagnostics and treatment. Molecular cytogenetic techniques like Fluorescence In Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH) are extensively used to detect chromosomal abnormalities and genetic mutations associated with various types of cancer. These techniques enable oncologists to identify specific biomarkers, predict patient outcomes, and tailor personalized treatment strategies such as targeted therapies and immunotherapies. The increasing prevalence of cancer globally, coupled with advancements in genomic technologies, continues to drive the dominance of oncology as a key application in the molecular cytogenetics market. Personalized medicine represents the rapidly growing segment within molecular cytogenetics.

Molecular Cytogenetics Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on Geography, the Global Molecular Cytogenetics Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the molecular cytogenetics market, North America stands out as the dominating geography, driven by advanced healthcare infrastructure, substantial investments in research and development, and a strong regulatory framework that supports innovation and commercialization of molecular cytogenetic products. The region's leadership is further bolstered by high prevalence rates of genetic disorders and cancers, which spur demand for advanced diagnostic solutions using techniques such as Fluorescence In Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH). Moreover, North America's proactive adoption of personalized medicine approaches contributes to the market's dominance, as healthcare providers increasingly rely on molecular cytogenetics for tailored treatment strategies and improved patient outcomes. Asia Pacific represents the rapidly growing segment in the molecular cytogenetics market, fueled by increasing healthcare expenditures, expanding healthcare infrastructure, and rising awareness about genetic testing and personalized medicine across countries like China, India, and Southeast Asian nations.

Key Players

The "Global Molecular Cytogenetics Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Abbott Laboratories, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, Leica Biosystems Nussloch GmbH, CytoTest, Inc., Bionano Genomics.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Molecular Cytogenetics Market Key Developments

In June 2023, Thermo Fisher Scientific launched a new generation of FISH probes with enhanced specificity and sensitivity for detecting chromosomal abnormalities associated with cancer and genetic disorders. These advanced probes are designed to improve diagnostic accuracy and support personalized medicine approaches.
In September 2022, Agilent Technologies introduced a next-generation array CGH platform capable of high-resolution genome-wide analysis. The platform integrates advanced bioinformatics tools for comprehensive genomic profiling, enabling researchers and clinicians to identify genetic variations linked to various diseases.
In March 2022, PerkinElmer announced the expansion of its molecular cytogenetics portfolio with the introduction of automated FISH assay systems. These systems streamline laboratory workflows, reduce hands-on time, and enhance throughput for high-volume diagnostic testing, particularly in oncology and prenatal diagnostics.
In December 2021, Illumina Inc. launched a new software platform for analyzing CGH data from its sequencing systems. The platform includes AI-powered algorithms for interpreting complex genomic data, providing researchers with actionable insights into chromosomal abnormalities and structural variations.
In August 2021, Oxford Gene Technology (OGT) introduced novel genomic in situ hybridization (GISH) probes for studying plant genomes. These probes enable researchers to visualize and analyze chromosomal organization and genetic variation in plants, supporting advancements in agricultural biotechnology.